Animal Capital

Texas-Based Colossal Achieves Unicorn Status With $150M Series B Raise, Plans To ‘De-Extinct’ the Dodo Bird

by | Jan 31, 2023
Colossal says its efforts could help boost "the U.S. high-tech advantage." Its gene editing technologies "will make waves across sectors—in agriculture with new biofuels and preserving biodiversity, as well as in human health through improved gene therapy and vaccine development," the company said.
MORE
Mammoth Project: Dallas’ Colossal Raises $60M to Advance Genetic Engineering and ‘De-Extinction’ Technologies
Colossal launched last September with a plan to "de-extinct" the woolly mammoth by using CRISPR genetic engineering to create a mammoth-elephant hybrid. With a total raise of $75 million to date, the startup aims to have its first set of mammoth-elephant hybrid calves "in 4 to 6 years," co-founder and CEO Ben Lamm told us. But Colossal's goals extend much further—with the potential "to advance human health, enhance food production, reduce environmental impact, and optimize animal health and welfare."
MORE